Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy

Both real-world and virtual patients maintained significant weight loss under reduced dosing frequencies.

• Reducing the frequency of incretin mimetic administration does not appear to significantly decrease weight loss efficacy.
• Patients waiting 2, 3, or even 4 weeks between doses still exhibited considerable weight maintenance.
• The findings suggest that less frequent dosing could serve as a viable strategy for long-term weight maintenance.
• Further validation is needed to confirm the effectiveness of this off-label approach and to establish optimal dosing regimens.

AI simplified